• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Teleretinal screening fails to do double duty for detecting glaucoma, cataracts

Digital EditionOphthalmology Times: November 15, 2020
Volume 45
Issue 19

Programs use detection and treatment to ease burden of eye disease.

Utilization of a diabetic eye disease teleretinal screening program to detect glaucoma and cataract is not yet feasible.

Instead, clinical examination remains the primary method of screening for the latter pathologies, concluded a team of investigators from Emory University in Atlanta, Georgia.

In a retrospective analysis of data collected from patients with type 1 or type 2 diabetes who had been screened via the Grady Health System’s teleretinal screening program, the investigators found only fair agreement between the results of screening based on nonmydriatic fundus camera images and clinical exam in regard to glaucoma diagnosis, slight agreement for detecting cataract, and slight agreement for detecting both pathologies combined.

Although the specificity and negative predictive value for the teleretinal screening program were both high for detecting glaucoma, cataract, and both together, its sensitivity and positive predictive value were low for all outcomes, according to investigators.

Related: Retinal pathologies challenging to image with current technologies

The research was presented at the 2020 Association for Research in Vision and Ophthalmology meeting by Omar I. Ali, BS, an MPH candidate at Emory University’s Rollins School of Public Health and a medical student at Baylor College of Medicine in Houston, Texas.

Yousuf M. Khalifa, MD, an associate professor of ophthalmology at Emory University School of Medicine, is the senior investigator in the study.

Reducing the burden
“Large teleretinal screening programs offer the potential to reduce the burden of eye disease through early detection and treatment,” Ali pointed out. “Such screening systems, however, should be both highly sensitive and highly specific when compared to the gold standard, which in our study was clinical examination.”

Ali also pointed out that additional research must be done on the best measures for accurate detection of glaucoma, because current telescreening programs differ on which aspects to give credence to, reflecting the general difficulty in diagnosing glaucoma clinically.

“In addition, further research is needed on the usefulness, cost-effectiveness, and accuracy of this type of screening system to better understand its role in a large healthcare system,” he said.

Related: Astigmatism management software proving to be accurate, precise​

Detecting secondary outcomes

Although the use of teleretinal screening programs to detect diabetic retinopathy and reduce barriers to access has spread across many communities and the benefits have been well reported, there is less investigation of utilizing the screening program to detect secondary outcomes, such as cataract or glaucoma.

According to Ali,the retrospective study was undertaken by investigators against that background.

Patients included in the study were identified from among those screened using a nonmydriatic camera via the Grady teleretinal screening program between January and October 2018.

Ali explained that the eligible patients had to meet the threshold for the primary outcome of having a positive screen for proliferative diabetic retinopathy (PDR) and/or diabetic macular edema (DME).

They also had to show evidence of cataract and/or glaucoma on the screening imaging, and have been seen in the clinic for follow-up of their primary outcome.

During the study period, a total of 7099 patients were screened through the teleretinal screening program, of which 394 screened positive for PDR and/or DME. Of the 394 patients, 299 were seen in clinic for follow-up, but only 16 of the 299 patients examined had glaucoma (n = 13) or cataract (n = 3) on screening.

Related: Exploring pathogenic cytokines as biomarkers for DME

Agreement between the findings from the screening and clinical exam was calculated using K; values were 0.23 for glaucoma, 0.01 for presence of cataract, and 0.04 for the combined endpoint. The sensitivity of teleretinal screening for detecting any of the secondary outcomes ranged from 4.55% to 16.67%, and it had a positive predictive value of 50% for all three.

According to Ali, its specialty was greater than 98% and negative predictive value ranged from 71% to almost 95%.

Ali said it is likely that the true sensitivity of the current teleretinal system is much higher, especially given the literature report of a teleglaucoma program having high specificity and sensitivity.

The investigators were pleased with the results of their research, butalso acknowledged the limitations of the study. Further research is needed, Ali explained.

“Our study was limited, however, due to its sample size, loss to follow up, and requirement for patients having to screen positive for both the primary outcome, PDR and/or DME, and the secondary outcome of glaucoma or cataract,” Ali concluded. “Further studies with larger sample sizes and better follow-up are needed to better understand the role of teleretinal screening for secondary outcomes.”

Read more by Cheryl Guttman Krader


Omar I. Ali, BS
Ali has no relevant financial relationships to disclose.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.